17:15 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

GW's GWP42006 misses in Phase IIa for focal seizures

GW Pharmaceuticals plc (NASDAQ:GWPH) reported preliminary data from a Phase IIa trial in 162 adults with inadequately controlled focal seizures showing that twice-daily GWP42006 as an add-on therapy missed the primary endpoint of reducing focal...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

Cannabidivarin: Phase II started

GW began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily oral GWP42006 plus antiepileptic drugs in patients with inadequately controlled focal seizures. GW and Otsuka partnered in 2007 to evaluate cannabinoid compounds for...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Clinical News

GWP42006: Phase I data

A double-blind, placebo-controlled, U.K. Phase I trial in 66 healthy volunteers showed that single and multiple doses of 25, 75, 200 and 400 mg oral GWP42006 were well tolerated with no serious adverse events or...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Clinical News

GWP42006: Phase I started

GW Pharma began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate single and multiple ascending-doses of 25, 75, 200 and 400 mg oral GWP42006 in about 55 healthy volunteers. The trial will evaluate GWP42006...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

GW Pharma, Otsuka Pharmaceutical preclinical data

In mice, >=50 mg/kg CBDV significantly reduced maximal electroshock-induced seizures and >=100 mg/kg CBDV significantly reduced audiogenic-induced seizures. In rats, >=100 mg/kg CBDV significantly reduced pentylenetetrazole-induced seizures. CBDV alone had no effect on pilocarpine-induced seizures,...